Abstract: Objective To evaluate clinical significance,feasibility and security of the PP and HF in treating severe hepatitis patients with liver failure. Methods Thirty-eight treatments of PP and HF were taken in 15 patients with severe hepatitis. The change of clinical symptoms, liver function, plasma thrombinogen time(PT) and ammonia were observed to determine the clinical effects. The feasibility and security were determined by therapy related adverse reactions and tolerance of the patients. Results After the treatment, the clinical symptoms such as conscious disturbance, jaundice, intertia, abdominal distention were better than before. The serum bilirubin decreased and PT increased significantly (P＜0.05). No severe hemorrhage, shock or other adverse reactions occurred. All patients could tolerate the therapy. Conclusion The therapy is safe and can significantly improve the symptoms, blood parameters and short-term mortality in patients with severe hepatitis.

Key words: Hemofiltration, Severe hepatitis, Liver failure